Overview

Pulmonary Hypertension and Anastrozole Trial

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in pulmonary arterial hypertension (PAH).
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Johns Hopkins University
National Heart, Lung, and Blood Institute (NHLBI)
Rhode Island Hospital
Stanford University
University of Colorado, Denver
Vanderbilt University
Washington University School of Medicine
Treatments:
Anastrozole